ScreenerHero

ALVO Alvotech

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · alvotech.com
5.850USD-4.72%Mkt Cap: 2.09B $P/E: —

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap2.09B USD
Enterprise Value3.50B USD
Revenue (TTM)494.61M USD
Gross Profit350.76M USD
Net Income (TTM)27.92M USD
Revenue/Share1.68 USD
Last Price5.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.3K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)26.89
PEG—
EV/EBITDA46.21
EV/Revenue7.08
P/S4.43
P/B-11.43
EPS (TTM)-0.62
EPS (Forward)0.23
52W Range
2.94048% of range9.045
52W High9.045 USD
52W Low2.940 USD
Profitability
Gross Margin59.82%
Oper. Margin-11.05%
EBITDA Margin15.31%
Profit Margin4.76%
ROE-9.81%
ROA1.88%
Growth
Revenue Growth-38.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.20M USD
CapEx (TTM)96.13M USD
FCF Margin-24.89%
FCF Yield-5.90%
Net Debt1.31B USD
Net Debt/EBITDA17.28
Balance Sheet
Debt/Equity-5.09
Current Ratio1.65
Quick Ratio0.79
Book Value/Sh-0.54 USD
Cash/Share0.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)6.800 USD
Upside (mean)+16.2%
Target Range4.000 USD – 9.000 USD
4.000+16.2% to mean9.000
# Analysts5
Ownership
Shares Out.356.82M
Float140.79M
Insiders59.68%
Institutions12.80%
Short Interest
Short Ratio5.8d
Short % Float3.61%
Short % Out.1.63%
Shares Short5.81M
Short (prev mo.)5.16M
Technical
SMA 504.793 (+22.0%)
SMA 2004.184 (+39.8%)
Beta0.20
S&P 52W Chg16.45%
Avg Vol (30d)1.27M
Avg Vol (10d)1.22M
Technical Indicators
RSI (14)58.0
MACD0.3298
MACD Signal0.3693
MACD Hist.-0.0395
BB Upper6.388 USD
BB Middle5.654 USD
BB Lower4.919 USD
BB Width25.99%
ATR (14)0.3440 USD
Vol Ratio (20d)0.67x